Drug intelligence / Profile preview

JV301

Development stage: Preclinical
Lead developer: Juvensis Therapeutics
Modality: Gene Therapies

Overview

JV301 is an adeno-associated virus (AAV)-based gene therapy candidate developed by Juvensis Therapeutics for the treatment of Alzheimer's disease. It utilizes precision telomere regulation technology to target the telomerase reverse transcriptase (TERT) pathway. By delivering the TERT gene or modulating telomerase activity, JV301 aims to counteract cellular senescence and telomere shortening, which are implicated in the pathogenesis of neurodegenerative disorders. The program is currently in the early discovery and preclinical stages of development.

Targets

TERT (Telomerase)

Beyond the preview

Go deeper on JV301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JV301.

Explore the full profile